Schizophrenia Clinical Trials in Chicago

View 37 new treatments for Schizophrenia in Chicago, IL, and nearby areas, such as Naperville. Every day, Power helps hundreds of schiz patients connect with leading medical research.
View 19 trials in Chicago
Filter (19)

Cariprazine for Pediatric Schizophrenia

AbbVie Clinic, Hoffman Estates + 3 more

This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.Show More

Verified

Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
ABBVIE INC.
Study Director

Emraclidine for Schizophrenia

Cerevel Clinic, Hoffman Estates + 3 more

This trial aims to evaluate the safety and tolerability of a medication called emraclidine, taken by mouth, in adults with schizophrenia.

Verified

Recruiting

No Placebo Trial

Phase 2
Est. 6 - 12 Weeks
Erica Koenig, PhD
Study Director

Clozapine vs Risperidone for Psychosis

Research Clinic, Chicago + 1 more

The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The study sample will be comprised of individuals with psychosis, including 1) schizophrenia, 2) schizoaffective disorder and 3) psychotic bipolar I disorder. The investigators plan to initially screen and recruit n=524 (from both the existing B-SNIP library and newly-identified psychosis cases, \~50% each) in order to enroll n=320 (B1 and B2) into the RCT.Show More
Recruiting
Phase 4
Est. 6 - 12 Weeks
Carol Tamminga, M.D.
Principal Investigator

KarXT for Schizophrenia

Karuna Clinic, Chicago + 3 more

This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Bruce Kinon, MD
Study Director

Long-term Safety of Iclepertin for Schizophrenia

Boehringer Ingelheim Clinic, Chicago + 1 more

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

Brilaroxazine for Schizophrenia

Reviva Clinic, Chicago + 1 more

This trial tests Brilaroxazine, a daily pill, in patients with severe mental health issues. It aims to improve mood and reduce symptoms. The study lasts for more than a year.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Medical Director
Study Director

SEP-363856 for Schizophrenia

Sunovion Clinic, Chicago + 1 more

This trial is testing a new schizophrenia medication called SEP-363856 in people who have already started using it. The goal is to see if it is safe and effective over several months. The medication works by affecting brain chemicals to help reduce symptoms of schizophrenia.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
CNS Medical Director
Study Chair

KarXT for Schizophrenia

Karuna Clinic, Chicago + 5 more

This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Bruce Kinon, MD
Study Director

Valbenazine for Schizophrenia

Neurocrine Clinic, Chicago + 1 more

This trial is testing whether adding the medication valbenazine can help people with schizophrenia who haven't improved enough with regular antipsychotic drugs. Valbenazine aims to balance brain chemicals to reduce symptoms.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Clinical Development Lead
Study Director

Dexmedetomidine for Agitation in Schizophrenia and Bipolar Disorder

BioXcel Clinic, Chicago + 3 more

In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Robert Risinger, MD
Study Chair
Page 1 of 2

Frequently Asked Questions

How much do schizophrenia clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do schizophrenia clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across schizophrenia trials in Chicago, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for schizophrenia patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Chicago is research being conducted for schizophrenia?

Clinical trials for schizophrenia in Chicago are being conducted at the Uptown Research Institute, located in the northern part of the city, with approximately 3 trials ongoing. Additionally, American Medical Research in the west area is involved with around 2 trials.

What promising new drugs are being tested?

In Chicago, schizophrenia research is focusing on treatments like Atypical Antipsychotics and NMDA receptor antagonists. Notable drugs being studied include Cariprazine, Clozapine, and CVL-231.